Shots:
- Revvity has launched SuperFlex, a compact immunoassay platform for rapid, reliable prenatal screening in lower-volume laboratories & clinics, incl. preeclampsia testing
- SuperFlex offers an affordable, low-waste setup with annual maintenance, simplified operation and minimal training, plus flexible throughput with continuous loading and results in as little as 14min
- SuperFlex supports first & second-trimester biochemical prenatal screening, offering a cost-effective random-access solution for decentralized testing; initial launch is expected in CE-mark accepting markets, with APAC expansion planned for late 2026
Ref: Businesswire | Image: Revvity | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
